Mitochondrial transcription elongation factor TEFM promotes malignant progression of gliomas.

Autor: Wang, Yin¹ (AUTHOR), Hu, Wenxuan² (AUTHOR), Zhou, Boya³ (AUTHOR), Zhao, Yu⁴ (AUTHOR), Tang, Yufei⁴ (AUTHOR), Deng, Zhiyong¹ (AUTHOR) yichun1988@yeah.net, Chen, Minbin^1,5 (AUTHOR) mbinchen@163.com

Publikováno v: Cancer Cell International. 12/24/2024, Vol. 24 Issue 1, p1-16. 16p.

Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.

Autor: Caruso HG; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, P.O. Box 301402, Houston, TX, 77030-1402, USA., Tanaka R; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Liang J; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, P.O. Box 301402, Houston, TX, 77030-1402, USA., Ling X; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, P.O. Box 301402, Houston, TX, 77030-1402, USA., Sabbagh A; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, P.O. Box 301402, Houston, TX, 77030-1402, USA., Henry VK; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, P.O. Box 301402, Houston, TX, 77030-1402, USA., Collier TL; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, P.O. Box 301402, Houston, TX, 77030-1402, USA., Heimberger AB; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, P.O. Box 301402, Houston, TX, 77030-1402, USA. aheimber@mdanderson.org.

Publikováno v: Journal of neuro-oncology [J Neurooncol] 2019 Dec; Vol. 145 (3), pp. 429-439. Date of Electronic Publication: 2019 Nov 04.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Autor: Molina JR; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sun Y; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Protopopova M; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gera S; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bandi M; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bristow C; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., McAfoos T; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morlacchi P; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Agilent Technologies Inc., Lexington, MA, USA., Ackroyd J; Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA., Agip AA; Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK., Al-Atrash G; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Asara J; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Bardenhagen J; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carrillo CC; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carroll C; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang E; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ciurea S; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cross JB; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Czako B; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Deem A; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., de Groot JF; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dong JW; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng N; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao G; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gay J; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Do MG; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Greer J; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Giuliani V; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Han J; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Han L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Henry VK; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hirst J; Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK., Huang S; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jiang Y; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kang Z; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khor T; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konoplev S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin YH; Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA., Liu G; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lodi A; Department of Nutritional Sciences, University of Texas at Austin, Austin, TX, USA., Lofton T; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ma H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahendra M; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Matre P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mullinax R; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Peoples M; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Petrocchi A; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodriguez-Canale J; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Serreli R; Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK., Shi T; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Smith M; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tabe Y; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Next Generation Hematology Laboratory Medicine, Department of Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan., Theroff J; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tiziani S; Department of Nutritional Sciences, University of Texas at Austin, Austin, TX, USA., Xu Q; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang Q; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Muller F; Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA., DePinho RA; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Toniatti C; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Draetta GF; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heffernan TP; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jones P; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Di Francesco ME; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.; Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.

Publikováno v: Nature medicine [Nat Med] 2018 Jul; Vol. 24 (7), pp. 1036-1046. Date of Electronic Publication: 2018 Jun 11.

Single-cell transcriptome sequencing reveals aberrantly activated inter-tumor cell signaling pathways in the development of clear cell renal cell carcinoma.

Autor: Zhang, Junfeng^1,2 (AUTHOR), Liu, Fuzhong³ (AUTHOR), Guo, Wenjia³ (AUTHOR), Bi, Xing¹ (AUTHOR), Yuan, Shuai¹ (AUTHOR), Shayiti, Fuerhaiti¹ (AUTHOR), Pan, Ting¹ (AUTHOR), Li, Kailing² (AUTHOR) 726589787@qq.com, Chen, Peng¹ (AUTHOR) chenpeng9@126.com

Publikováno v: Journal of Translational Medicine. 1/8/2024, Vol. 22 Issue 1, p1-18. 18p.

Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.

Autor: Wang, Xinzhuang¹ (AUTHOR) wangxinzhuang0920@163.com, Zhang, Hong² (AUTHOR), Zhang, Mingchu¹ (AUTHOR), Zhang, Xuezhi¹ (AUTHOR), Mao, Wenbin¹ (AUTHOR), Gao, Ming³ (AUTHOR)

Publikováno v: BMC Cancer. 5/8/2023, Vol. 23 Issue 1, p1-11. 11p.